Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adma Biologics Inc | ADMA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.88 | 04:01:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.88 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.945 - 4.65 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.88 | USD |
Adma Biologics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 876.75M | 225.97M | - | 154.08M | -65.9M | -0.29 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adma Biologics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.83 | 3.90 | 3.64 | 3.76 | 1,406,771 | 0.05 | 1.31% |
| 1 Month | 3.66 | 4.07 | 3.56 | 3.83 | 1,888,393 | 0.22 | 6.01% |
| 3 Months | 3.82 | 4.07 | 3.06 | 3.58 | 1,855,901 | 0.06 | 1.57% |
| 6 Months | 4.02 | 4.65 | 3.06 | 3.80 | 2,036,474 | -0.14 | -3.48% |
| 1 Year | 3.38 | 4.65 | 2.945 | 3.66 | 2,342,836 | 0.50 | 14.79% |
| 3 Years | 2.01 | 4.65 | 1.01 | 2.41 | 3,043,866 | 1.87 | 93.03% |
| 5 Years | 4.93 | 7.04 | 1.01 | 2.64 | 2,642,423 | -1.05 | -21.3% |
Adma Biologics Description
| ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. |
